Literature DB >> 19164531

Conformational disturbance in Abl kinase upon mutation and deregulation.

Roxana E Iacob1, Teodora Pene-Dumitrescu, Jianming Zhang, Nathanael S Gray, Thomas E Smithgall, John R Engen.   

Abstract

Protein dynamics are inextricably linked to protein function but there are few techniques that allow protein dynamics to be conveniently interrogated. For example, mutations and translocations give rise to aberrant proteins such as Bcr-Abl where changes in protein conformation and dynamics are believed to result in deregulated kinase activity that provides the oncogenic signal in chronic myelogeous leukemia. Although crystal structures of the down-regulated c-Abl kinase core have been reported, the conformational impact of mutations that render Abl resistant to small-molecule kinase inhibitors are largely unknown as is the allosteric interplay of the various regulatory elements of the protein. Hydrogen exchange mass spectrometry (HX MS) was used to compare the conformations of wild-type Abl with a nonmyristoylated form and with 3 clinically relevant imatinib resistance mutants (T315I, Y253H and E255V). A HX-resistant core localized to the interface between the SH2 and kinase domains, a region known to be important for maintaining the down-regulated state. Conformational differences upon demyristoylation were consistent with the SH2 domain moving to the top of the small lobe of the kinase domain as a function of activation. There were conformational changes in the T315I mutant but, surprisingly, no major changes in conformation were detected in either the Y253H or the E255V mutants. Taken together, these results provide evidence that allosteric interactions and conformational changes play a major role in Abl kinase regulation in solution. Similar analyses could be performed on any protein to provide mechanistic details about conformational changes and protein function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164531      PMCID: PMC2635808          DOI: 10.1073/pnas.0811912106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism.

Authors:  Alexandr P Kornev; Nina M Haste; Susan S Taylor; Lynn F Ten Eyck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

2.  The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.

Authors:  Shugui Chen; Sébastien Brier; Thomas E Smithgall; John R Engen
Journal:  Protein Sci       Date:  2007-02-27       Impact factor: 6.725

3.  Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

Authors:  Brian J Skaggs; Mercedes E Gorre; Ann Ryvkin; Michael R Burgess; Yongming Xie; Yun Han; Evangelia Komisopoulou; Lauren M Brown; Joseph A Loo; Elliot M Landaw; Charles L Sawyers; Thomas G Graeber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

4.  HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction.

Authors:  Ronald P Trible; Lori Emert-Sedlak; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2006-07-18       Impact factor: 5.157

5.  Abl N-terminal cap stabilization of SH3 domain dynamics.

Authors:  Shugui Chen; Teodora Pene Dumitrescu; Thomas E Smithgall; John R Engen
Journal:  Biochemistry       Date:  2008-05-02       Impact factor: 3.162

6.  High-speed and high-resolution UPLC separation at zero degrees Celsius.

Authors:  Thomas E Wales; Keith E Fadgen; Geoff C Gerhardt; John R Engen
Journal:  Anal Chem       Date:  2008-08-02       Impact factor: 6.986

7.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

Authors:  Michele Modugno; Elena Casale; Chiara Soncini; Pamela Rosettani; Riccardo Colombo; Rosita Lupi; Luisa Rusconi; Daniele Fancelli; Patrizia Carpinelli; Alexander D Cameron; Antonella Isacchi; Jürgen Moll
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.

Authors:  Navratna Vajpai; André Strauss; Gabriele Fendrich; Sandra W Cowan-Jacob; Paul W Manley; Stephan Grzesiek; Wolfgang Jahnke
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

9.  Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Authors:  Panagis Filippakopoulos; Michael Kofler; Oliver Hantschel; Gerald D Gish; Florian Grebien; Eidarus Salah; Philipp Neudecker; Lewis E Kay; Benjamin E Turk; Giulio Superti-Furga; Tony Pawson; Stefan Knapp
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

10.  Activation of tyrosine kinases by mutation of the gatekeeper threonine.

Authors:  Mohammad Azam; Markus A Seeliger; Nathanael S Gray; John Kuriyan; George Q Daley
Journal:  Nat Struct Mol Biol       Date:  2008-09-14       Impact factor: 15.369

View more
  40 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Noncanonical role of the PDZ4 domain of the adaptor protein PDZK1 in the regulation of the hepatic high density lipoprotein receptor scavenger receptor class B, type I (SR-BI).

Authors:  Kosuke Tsukamoto; Thomas E Wales; Kathleen Daniels; Rinku Pal; Ren Sheng; Wonhwa Cho; Walter Stafford; John R Engen; Monty Krieger; Olivier Kocher
Journal:  J Biol Chem       Date:  2013-05-17       Impact factor: 5.157

3.  Affinity reagents that target a specific inactive form of protein kinases.

Authors:  Pratistha Ranjitkar; Amanda M Brock; Dustin J Maly
Journal:  Chem Biol       Date:  2010-02-26

Review 4.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

5.  Molecular Basis of the Mechanisms Controlling MASTL.

Authors:  Dario Hermida; Gulnahar B Mortuza; Anna-Kathrine Pedersen; Irina Pozdnyakova; Tam T T N Nguyen; Maria Maroto; Michael Williamson; Tasja Ebersole; Giuseppe Cazzamali; Kasper Rand; Jesper V Olsen; Marcos Malumbres; Guillermo Montoya
Journal:  Mol Cell Proteomics       Date:  2019-12-18       Impact factor: 5.911

6.  Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.

Authors:  Shoghag Panjarian; Roxana E Iacob; Shugui Chen; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2013-01-09       Impact factor: 5.157

Review 7.  Hydrogen exchange mass spectrometry: are we out of the quicksand?

Authors:  Roxana E Iacob; John R Engen
Journal:  J Am Soc Mass Spectrom       Date:  2012-04-03       Impact factor: 3.109

8.  Nitric oxide-induced conformational changes in soluble guanylate cyclase.

Authors:  Eric S Underbakke; Anthony T Iavarone; Michael J Chalmers; Bruce D Pascal; Scott Novick; Patrick R Griffin; Michael A Marletta
Journal:  Structure       Date:  2014-02-20       Impact factor: 5.006

9.  Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.

Authors:  Anshuman Dixit; Gennady M Verkhivker
Journal:  PLoS Comput Biol       Date:  2009-08-28       Impact factor: 4.475

Review 10.  SH2 domains: modulators of nonreceptor tyrosine kinase activity.

Authors:  Panagis Filippakopoulos; Susanne Müller; Stefan Knapp
Journal:  Curr Opin Struct Biol       Date:  2009-11-18       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.